Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
29.19
-0.46 (-1.55%)
At close: Mar 10, 2026, 4:00 PM EDT
29.53
+0.34 (1.16%)
After-hours: Mar 10, 2026, 6:55 PM EDT
Viridian Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Viridian Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $41.17, which forecasts a 41.04% increase in the stock price over the next year. The lowest target is $29 and the highest is $61.
Price Target: $41.17 (+41.04%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 6 | 5 | 6 | 6 | 6 |
| Buy | 5 | 4 | 6 | 6 | 6 | 6 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $45 → $42 | Buy | Maintains | $45 → $42 | +43.88% | Feb 27, 2026 |
| Needham | Needham | Strong Buy Reiterates $42 | Strong Buy | Reiterates | $42 | +43.88% | Feb 4, 2026 |
| Wells Fargo | Wells Fargo | Hold Maintains $26 → $29 | Hold | Maintains | $26 → $29 | -0.65% | Feb 3, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $41 → $40 | Strong Buy | Maintains | $41 → $40 | +37.03% | Jan 8, 2026 |
| UBS | UBS | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +71.29% | Jan 7, 2026 |
Financial Forecast
Revenue This Year
74.16M
from 70.85M
Increased by 4.67%
Revenue Next Year
320.03M
from 74.16M
Increased by 331.57%
EPS This Year
-3.81
from -3.32
EPS Next Year
-2.18
from -3.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 217.7M | 665.2M | |||
| Avg | 74.2M | 320.0M | |||
| Low | 14.8M | 131.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 207.2% | 797.0% | |||
| Avg | 4.7% | 331.6% | |||
| Low | -79.1% | 77.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.87 | -0.45 | |||
| Avg | -3.81 | -2.18 | |||
| Low | -4.64 | -4.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.